Navigation Links
International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis

WORCESTER, Massachusetts, July 08, 2007 /PRNewswire/ --

- ENDORSE Global Findings Highlight the Need to Urgently Implement Hospital-Wide Strategies to Optimize VTE Management: Systematically Assess Patient Risk for VTE and Provide Appropriate prophylaxis to Prevent VTE

Venous thromboembolism (VTE) risk is high among hospital patients and most of these at-risk patients are not protected with adequate prophylaxis according to data from the international ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) study presented today at the XXIst International Society on Thrombosis and Haemostasis (ISTH) congress in Geneva.

VTE is a preventable disease which contributes significantly to morbidity and mortality among patients hospitalized for acute medical and surgical illnesses. Many complications and deaths due to VTE could be prevented using thromboprophylaxis as recommended by evidence based guidelines, but some studies have shown that there is a gap between evidence and practice in the hospital setting. Lack of awareness and uncertainty about the prevalence of patients at risk for VTE are among the major reasons accounting for this gap (1, 2). To date, there has been no large international study performed in hospitals selected at random around the world to evaluate VTE risk and prophylaxis practice globally.

ENDORSE collected data on more than 60,000 patients who were surveyed across 358 acute care hospitals randomly selected in 32 countries, encompassing 5 continents. All participating hospitals followed the same standard multinational protocol to survey the patients present in the wards.

The main objectives of ENDORSE were to assess the prevalence of VTE risk in the acute hospital care setting and to determine the proportion of at-risk patients who receive recommended prophylaxis using the d
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
6. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:10/1/2014)... (NYSE: RMD ), a pioneer and innovator in ... sleep apnea solutions specifically for women, is launching a new ... night,s sleep. The Better Sleep For Women ... just part of living a busy life. It will encourage ... health, essential to not only living an active lifestyle but ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems ... will report results for the fourth quarter of fiscal ... Wednesday, October 22, 2014.  The news release will be ... at 2:00 p.m. PT.  The news release and a ... on the company website at: www.varian.com/investor .  To ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal ... PHIA) today announced its eCareCoordinator and eCareCompanion telehealth ... Food and Drug Administration (FDA). A part of ... programs , eCareCoordinator and eCareCompanion are focused on ... first clinical applications to be available through the ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4
... Jan. 11, 2011 Reportlinker.com announces that a ... catalogue: Novo Nordisk A/S: PharmaVitae ... Introduction This ... Novo Nordisk in the prescription pharmaceutical sector. The ...
... 11, 2011 Reportlinker.com announces that ... available in its catalogue: ... New pricing rules set to negatively ... internationally http://www.reportlinker.com/p0360217/Germany-Pharmaceutical-Market-Overview-–-New-pricing-rules-set-to-negatively-impact-drug-sales-both-domestically-and-internationally.html ...
Cached Medicine Technology:Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile 2Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally 2
(Date:10/1/2014)... beta-amyloid is strongly associated with Alzheimer,s disease; however, researchers ... is the causal agent of the onset and development ... is that beta-amyloid is not harmful when found in ... it self-assembles to form the so-called amyloid fibrils , ... alone, but with multiple ones because each aggregate of ...
(Date:10/1/2014)... by the Engineering and Physical Sciences Research Council ... UK,s vital industrial control systems which run, for ... and the rail network. , The research ... or malware infiltrating the systems behind our critical ... Trustworthy Industrial Control Systems (RITICS), based at Imperial ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post ... , Senior citizens can qualify for affordable term ... seniors who are over 50 years old. Some term ... medical examination. , Term life insurance with a simplified ... qualify. Having life insurance during retirement is important for ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... new study shows men with prostate cancer who receive a ... reduce // the risk of recurrence after surgery may be ... showed men treated with androgen deprivation therapy (ADT) after prostate ... most common among women. Men who are older, smoke, or ...
... with the oral drug bosentan (Tracleer) has led to ... hypertension ( PAH) // . ,PAH is usually ... believed to cause the overproduction of endothelin, which increases ... This chronic obstruction leads to PAH, a condition that ...
... intense course of radiation after a lumpectomy may be ... on findings of a recent study. Standard treatment for ... weeks of radiation daily after undergoing surgery , however ... treatment is a major inconvenience leading them to choose ...
... a urinary tract infection can increase your chances of having ... few days, say researchers based on findings of a recent ... anytime we have an infection, to atherosclerosis, or clogging of ... of infections, some have speculated they, too, could aggravate the ...
... the existing drugs on the market are losing their ... bacteria hence researchers feel that the ocean is a ... ,More than 1 million microorganisms fill every milliliter of ... for some of our deadliest diseases. Many marine organisms ...
... J. Rutter, a well known scientist and accomplished businessman ... patent applications,has announced intention to set up a high ... of "Hemogenomics", which will be a marketing, selling and ... the sidelines of the BioAsia 2004 conference Bangalore on ...
Cached Medicine News:
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Medicine Products: